Meta-analysis reveals discrepant cardiotoxicity risks between trial and observational cohorts receiving immune checkpoint inhibitors, highlighting the need for accurate risk assessment.
Immune checkpoint inhibitors (ICIs) have uncommon associations with cardiotoxicity, yet these cardiotoxic effects are associated with high mortality. An accurate assessment of risk for cardiotoxicity is essential for clinical decision-making, but data from randomized controlled trials often differ from real-world observational studies.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: